Stifel analyst Bradley Canino lowered the price target on Affimed Therapeutics (NASDAQ: AFMD) to $11.00 (from $12.00) while maintaining a ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE